

Inventor: Indu Parikh
U.S. Serial No.: 09/282,471
Filing Date: March 31, 1999

Attorney Docket No.: 28069-547CIP2
(Formerly: 401865/SKYEPHARMA)

In the Specification:

Please replace the last paragraph on page 4 of the instant specification as follows:

Although we do not wish to be bound by any particular theory, it appears that these surface modifiers, ~~generally~~, that is phospholipids and one or more surfactants, ~~generally~~ absorb to the surfaces of fenofibrate, and modify the surfaces to allow smaller particle formation and ~~stailize~~ stabilize the formed microparticles. The concentrations of surface modifiers used in the process described here are normally above their critical micelle concentrations (CMC) and hence facilitate the formation of sub-micron to micron particles by stabilizing the particles.

Please replace the first paragraph on page 7, lines 1-12, of the instant specification, as follows:

It is thought that some of the functions of the second surface modifier(s) as ~~it relates they~~ relate to this invention are (a) allowing the formation of microparticles ~~that are~~ that are about 50% or smaller than the size ~~of microparticles~~ produced with phospholipid alone[,] ; (b) suppressing the process of Ostwald Ripening and therefore maintaining the particle size[,] ; (c) increasing the storage stability, minimizing sedimentation, and decreasing the particle growth during lyophilization and reconstitution; (d) adhering or coating firmly onto the surfaces of water-insoluble drug particles and therefore modifying the interfaces between the particles and the liquid in the resulting formulations; (e) increasing the interface compatibility between water-insoluble drug particles and the liquid; and (f) possibly orienting ~~themselves~~ themselves preferentially ~~themselves~~ with the hydrophilic portion sticking into the aqueous solution and the lipophilic portion strongly adsorbed at the water-insoluble drug particle surfaces.